ALDEYRA THERAPEUTICS INC (ALDX)
US01438T1060 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A -21.49% | N/A 101.10% | N/A 53.12% | N/A 17.01% | N/A 16.50% | N/A 11.41% | N/A -11.57% | |||||||||||
| EBITDA YoY % growth | -7.27M | -11.97M -64.65% | -18.66M -55.89% | -22.45M -20.31% | -39.63M -76.53% | -56.4M -42.32% | -34.61M 38.63% | -55.96M -61.69% | -62.42M -11.54% | -42.531M 31.86% | N/A -53.32% | N/A 15.83% | N/A 72.06% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -7.27M | -11.99M -64.92% | -18.7M -55.96% | -22.49M -20.27% | -39.7M -76.52% | -56.5M -42.32% | -34.67M 38.64% | -56.22M -62.16% | -62.68M -11.49% | -42.794M 31.73% | N/A -41.00% | N/A 97.16% | N/A -603.57% | N/A 51.44% | N/A 672.80% | N/A 152.59% | N/A 33.30% | N/A 19.53% | N/A -13.88% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -1.40 37.80% | -1.67 -19.29% | -1.40 16.17% | -1.90 -35.71% | -2.23 -17.37% | -1.12 49.78% | -1.07 4.36% | -1.06 1.04% | -0.64 39.62% | N/A -46.23% | N/A 50.69% | N/A 56.15% | N/A 480.54% | N/A 89.40% | N/A -17.48% | N/A 16.10% | N/A 1.46% | N/A 2.16% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.23 -187.19% | -0.22 -60.29% | -0.22 19.86% | -0.26 -2.00% | -0.26 -10.99% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -18.8M -222.19% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.505M -154.27% | -14.28M -52.01% | -14.28M 20.70% | -16.32M -1.13% | -16.32M -5.26% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.25 -78.57% | -0.25 | 0.00 | 0.77% |
| Q2 2024 Q2Q % growth | -0.28 -86.67% | -0.14 | -0.14 | -93.66% |
| Q1 2024 Q2Q % growth | -0.14 48.15% | -0.11 | -0.03 | -24.07% |
| Q4 2023 Q2Q % growth | -0.08 63.64% | -0.14 | 0.06 | 44.08% |
| Q3 2023 Q2Q % growth | -0.14 44.00% | -0.24 | 0.10 | 42.43% |
| Q2 2023 Q2Q % growth | -0.15 50.00% | -0.32 | 0.17 | 52.70% |
| Q1 2023 Q2Q % growth | -0.27 6.90% | -0.30 | 0.03 | 9.21% |
| Q4 2022 Q2Q % growth | -0.22 18.86% | -0.32 | 0.10 | 31.12% |
| Q3 2022 Q2Q % growth | -0.25 7.41% | -0.35 | 0.10 | 28.75% |
| Q2 2022 Q2Q % growth | -0.30 -7.14% | -0.32 | 0.02 | 5.35% |
| Q1 2022 Q2Q % growth | -0.29 -16.00% | -0.32 | 0.03 | 9.80% |
| Q4 2021 Q2Q % growth | -0.27 9.62% | -0.29 | 0.02 | 6.18% |
| Q3 2021 Q2Q % growth | -0.27 -17.39% | -0.27 | 0.00 | -0.78% |
| Q2 2021 Q2Q % growth | -0.28 -12.00% | -0.25 | -0.03 | -13.49% |
| Q1 2021 Q2Q % growth | -0.25 26.47% | -0.27 | 0.02 | 8.32% |
| Q4 2020 Q2Q % growth | -0.30 36.17% | -0.29 | -0.01 | -3.85% |
| Q3 2020 Q2Q % growth | -0.23 66.67% | -0.28 | 0.05 | 17.78% |
| Q2 2020 Q2Q % growth | -0.25 48.98% | -0.35 | 0.10 | 28.16% |
| Q1 2020 Q2Q % growth | -0.34 41.38% | -0.49 | 0.15 | 30.12% |
| Q4 2019 Q2Q % growth | -0.47 | -0.73 | 0.26 | 35.67% |
| Q3 2019 Q2Q % growth | -0.69 | -0.56 | -0.13 | -23.03% |
| Q2 2019 Q2Q % growth | -0.49 | -0.50 | 0.01 | 1.12% |
| Q1 2019 Q2Q % growth | -0.58 | -0.44 | -0.14 | -33.08% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | 2.04M | -2.04M | -100.00% | |
| Q4 2023 Q2Q % growth | 1.894M | -1.894M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -198.85% | -0.51% | -36.65% |
| Revenue | N/A | -100% | N/A | -100% |